Cardiovascular risk markers in patients with psoriatic arthritis: A meta-analysis of literature studies

Annals of Medicine

Volumn 47, Issue 4, 2015, Pages 346-353

  Di Minno, Matteo Nicola Dario ^a   Ambrosino, Pasquale ^b   Lupoli, Roberta ^b   Di Minno, Alessandro ^a   Tasso, Marco ^b   Peluso, Rosario ^b   Tremoli, Elena ^a  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Carotid plaques; Flow mediated dilation; Intima media thickness; Psoriatic arthritis; Subclinical atherosclerosis

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROTIC PLAQUE; AUGMENTATION INDEX; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BODY MASS; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; COMMON CAROTID ARTERY; DAS28; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE DURATION; EMBASE; ERYTHROCYTE SEDIMENTATION RATE; FLOW MEDIATED DILATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MEDICAL LITERATURE; MEDLINE; OBESITY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PUBLISHING; PULSE WAVE; REMISSION; RISK ASSESSMENT; SCOPUS; SYSTEMATIC REVIEW; VASODILATATION; WEB OF SCIENCE; ADULT; CARDIOVASCULAR DISEASE; FEMALE; MALE; META ANALYSIS; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

ADULT; ARTHRITIS, PSORIATIC; BIOMARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84930509080     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2015.1031822     Document Type: Article

References (59)

1. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classi fi cation criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54: 2665-73.
2. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64: ii14-17.
3. Peluso R, Iervolino S, Vitiello M, Bruner V, Lupoli G, Di Minno MN. Extra-articular manifestations in psoriatic arthritis patients. Clin Rheumatol. 2015;34: 745-53.
4. Husted JA, Thavaneswaran A, Chandran V, Eder L. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison. Arthritis Care Res (Hoboken). 2011;63: 1729-35.
5. Edson-Heredia E, Zhu B, Lefevre C, Wang M, Barrett A, Bushe CJ, et al. Prevalence and incidence rates of cardiovascular, autoimmune, and other diseases in patients with psoriatic or psoriatic arthritis: a retrospective study using Clinical Practice Research Datalink. J Eur Acad Dermatol Venereol. 2014 Oct 28. [Epub ahead of print]
6. Di Minno MN, Iervolino S, Lupoli R, Russolillo A, Coppola A, Peluso R, et al. Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis. Semin Thromb Hemost. 2012;38: 497-505.
7. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997;40: 1868-72.
8. Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68: 1131-5.
9. Jamnitski A, Visman IM, Peters MJ, Boers M, Dijkmans BA, Nurmohamed MT. Prevalence of cardiovascular diseases in psoriatic arthritis resembles that of rheumatoid arthritis. Ann Rheum Dis. 2011;70: 875-6.
10. Simon A, Chironi G, Levenson J. The performance of subclinical arterial disease detection as screening test for coronary heart disease. Hypertension. 2006;48: 392-6.
11. Bots ML, Grobbee DE. Intima media thickness as a surrogate marker for generalised atherosclerosis. Cardiovasc Drugs Ther. 2002;16: 341-51.
12. de Groot E, Hovingh GK, Wiegman A, Duriez P, Smit AJ, Fruchart JC, et al. Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation. 2004;109: 333-8.
13. O' Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340: 14-22.
14. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol. 1997;146: 483-94.
15. Belcaro G, Nicolaides AN, Ramaswami G, Cesarone MR, De Sanctis M, Incandela L, et al. Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVE study. Atherosclerosis. 2011;156: 379-87.
16. Calabia J, Torguet P, Garcia M, Garcia I, Martin N, Guasch B, et al. Doppler ultrasound in the measurement of pulse wave velocity: agreement with the Complior method Cardiovascular Ultrasound. 2011;9: 13.
17. Khan TH, Falahat AF, Niazi K. Critical review of the ankle brachial index. Curr Cardiol Rev. 2008;4: 101-6.
18. Atzeni F, Sarzi-Puttini P, Sitia S, Tomasoni L, Gianturco L, Battellino M, et al. Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. J Rheumatol. 2011;38: 1661-4.
19. Contessa C, Ramonda R, Lo Nigro A, Modesti V, Lorenzin M, Puato M, et al. Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data. Reumatismo. 2009;61: 298-305.
20. Sharma A, Reddy MH, Sharma K, Dogra S, Vijayvergiya R. Study of endothelial dysfunction in patients of psoriatic arthritis by flow mediated and nitroglycerine mediated dilatation of brachial artery. Int J Rheum Dis. 2014 Apr 4. [Epub ahead of print]
21. Karadag AS, Yavuz B, Ertugrul DT, Akin KO, Yalcin AA, Deveci OS, et al. Is psoriasis a pre-atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis. Int J Dermatol. 2010;49: 642-6.
22. Costa L, Caso F, D'Elia L, Atteno M, Peluso R, Del Puente A, et al. Psoriatic arthritis is associated with increased arterial stiff ness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol. 2012;31: 711-15.
23. Shang Q, Tam LS, Sanderson JE, Sun JP, Li EK, Yu CM. Increase in ventricular-arterial stiff ness in patients with psoriatic arthritis. Rheumatology (Oxford). 2012;51: 2215-23.
24. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G;CaRRDs study group. Carotid intima-media thickness in psoriatic arthritis: Differences between tumor necrosis factor-blockers and traditional disease-modifying antirheumatic drugs. Arterioscler Thromb Vasc Biol. 2011;31: 705-12.
25. Puato M, Ramonda R, Doria A, Rattazzi M, Faggin E, Balbi G, et al. Impact of hypertension on vascular remodeling in patients with psoriatic arthritis. J Hum Hypertens. 2014;28: 105-10.
26. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6: e1000097.
27. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available from: http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm. [Accessed on 8th April 2015].
28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327: 557-60.
29. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323: 101-5.
30. Bilgen SA, Kalyoncu U, Kilic L, Karadag O, Canpolat U, Aytemir K, et al. Subclinical atherosclerosis found both in psoriatic arthritis and rheumatoid arthritis. Ann Rheum Dis. 2013;72: A970.
31. Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol. 2008;35: 877-82.
32. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007;57: 1074-80.
33. Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum. 2007;36: 203-9.
34. Magro-Checa C, Orgaz-Molina J, Rosales-Alexander JL, Salvatierra J, Arias-Santiago S, Cantero-Hinojosa J, et al. Comparison of subclinical carotid atherosclerosis in patients with psoriatic arthritis, psoriasis alone and controls. Ann Rheum Dis. 2013;71: 572.
35. Peluso R, Costa L, Caso F, Atteno M, Iervolino S, Del Puente A, et al. Intima media wall thickness (A-IMT) is increased in patients with psoriatic arthritis. Rheumatology (Oxford). 2009:153: 80.
36. Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum. 2008;59: 1322-31.
37. Gentile M, Iervolino S, Peluso R, Di Minno D, De Simone B, Iannuzzo G, et al. Association between small dense LDL and psoriatic arthritis. Gior Ital Atrter. 2011;3: 70.
38. Profumo E, Di Franco M, Buttari B, Masella R, Filesi C, Tosti ME, et al. Biomarkers of subclinical atherosclerosis in patients with autoimmune disorders. Mediators Infl amm. 2012;2012: 503942.
39. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from: URL: www.cochrane-handbook.org [Accessed on 8th April 2015].
40. Ambrosino P, Lupoli R, Di Minno A, Iervolino S, Peluso R, Di Minno MN. Markers of cardiovascular risk in patients with antiphospholipid syndrome: a meta-analysis of literature studies. Ann Med. 2014;46: 693-702.
41. Ambrosino P, Lupoli R, Di Minno A, Tasso M, Peluso R, Di Minno MN. Subclinical atherosclerosis in patients with rheumatoid arthritis. A meta-analysis of literature studies. Thromb Haemost. 2015;113. [Epub ahead of print]
42. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5: 444-70.
43. Zhu TY, Li EK, Tam LS. Cardiovascular risk in patients with psoriatic arthritis. Int J Rheumatol. 2012;2012: 714321.
44. van den Oever IA, van Sijl AM, Nurmohamed MT. Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion. Ther Adv Musculoskelet Dis. 2013;5: 166-81.
45. Willerson T, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109: 22-10.
46. Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fi brinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol. 1999;19: 1368-77.
47. Laurent MR, Panayi GS, Shepherd P. Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis. 1981;40: 66-9.
48. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 1998;41: 1103-10.
49. Wang F, Wang NS, Yan CG, Li JH, Tang LQ. The significance of platelet activation in rheumatoid arthritis. Clin Rheumatol. 2007;26: 768-71.
50. Di Minno MN, Iervolino S, Peluso R, Scarpa R, Di Minno G. Platelet reactivity and disease activity in subjects with psoriatic arthritis. J Rheumatol. 2012;39: 334-6.
51. van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: The Rotterdam Study. Circulation. 2004;109: 1089-94.
52. Baldassarre D, Veglia F, Hamsten A, Humphries SE, Rauramaa R, de Faire U, et al. Progression of carotid intima-media thickness as predictor of vascular events: results from the IMPROVE study. Arterioscler Thromb Vasc Biol. 2013;33: 2273-9.
53. Green DJ, Jones H, Thijssen D, Cable NT, Atkinson G. Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension. 2011;57: 363-9.
54. Cooke JP, Tsao PS. Is NOan endogenous antiatherogenic molecule? Arterioscler Thromb. 1994;14: 653-55.
55. Shimbo D, Grahame-Clarke C, Miyake Y, Rodriguez C, Sciacca R, Di Tullio M, et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis. 2007;192: 197-203.
56. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69: 325-31.
57. Soltész P, Kerekes G, Dér H, Szücs G, SzántóS, Kiss E, et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev. 2011;10: 416-25.
58. Doshi SN, Naka KK, Payne N, Jones CJ, Ashton M, Lewis MJ, et al. Flow-mediated dilatation following wrist and upper arm occlusion in humans: the contribution of nitric oxide. Clin Sci. 2001;101: 629-35.
59. Mullen MJ, Kharbanda RK, Cross J, Donald AE, Taylor M, Vallance P, et al. Heterogenous nature of flow-mediated dilatation in human conduit arteries in vivo. Circ Res. 2001;88: 145-51.